Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival

Modern Pathology

Volumn 29, Issue 6, 2016, Pages 582-590

  Cleven, Arjen H G ^a   Al Sannaa, Ghadah A ^b   Briaire de Bruijn, Inge ^a   Ingram, Davis R ^b   Van De Rijn, Matt ^c   Rubin, Brian P ^d   De Vries, Maurits W ^a   Watson, Kelsey L ^b   Torres, Kelia E ^b   Wang, Wei Lien ^b   Van Duinen, Sjoerd G ^a   Hogendoorn, Pancras C W ^a   Lazar, Alexander J ^b   Bovée, Judith V M G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TEXAS   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3K27; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; HISTONE; LYSINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHILD; DERMATOFIBROSARCOMA PROTUBERANS; FEMALE; FIBROSARCOMATOUS DERMATOFIBROSARCOMA PROTUBERANS; HISTONE METHYLATION; HISTONE TRIMETHYLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SYNOVIAL SARCOMA; TISSUE MICROARRAY; CALIFORNIA; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NETHERLANDS; PATHOLOGY; PREDICTIVE VALUE; PRESCHOOL CHILD; PROGNOSIS; TEXAS; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CALIFORNIA; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; DNA METHYLATION; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYSINE; MALE; MIDDLE AGED; NETHERLANDS; NEURILEMMOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TEXAS; TIME FACTORS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84961226206     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.45     Document Type: Article

References (23)

1. Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. Malignant peripheral nerve sheath tumour. Hogendoorn PCW, Mertens F (eds). WHO Classification of Tumours of Soft Tissue and Bone. InterNational Agency for Research on Cancer (IARC): France, 2013, p187.
2. Goldblum JR, Folpe AL, Weiss SW. Malignant peripheral nerve sheath tumors. Goldblum JR, Folpe AL, Weiss SW (eds). Soft Tissue Tumors. 6th edn. Elsevier Saunders: USA, 2014, p 867.
3. Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol. 2011; 22: 207-214.
4. Nonaka D, Chiriboga L, Rubin BP. Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol. 2008; 35: 1014-1019.
5. Hirose T, Hasegawa T, Kudo E, et al. Malignant peripheral nerve sheath tumors: an immunohistochemical study in relation to ultrastructural features. Hum Pathol. 1992; 23: 865-870.
6. Sabah M, Cummins R, Leader M, et al. Loss of p16 (INK4A) expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected malignant peripheral nerve sheath tumors. Appl Immunohistochem Mol Morphol. 2006; 14: 97-102.
7. Pekmezci M, Reuss DE, Hirbe AC, et al. Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Mod Pathol. 2015; 28: 187-200.
8. Lee W, Teckie S, Wiesner T, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014; 46: 1227-1232.
9. Zhang M, Wang Y, Jones S, et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet. 2014; 46: 1170-1172.
10. Zou C, Smith KD, Liu J, et al. pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009; 249: 1014-1022.
11. Nielsen TO, Hsu FD, O'Connell JX, et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol. 2003; 163: 1449-1456.
12. Terry J, Saito T, Subramanian S, et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol. 2007; 31: 240-246.
13. Karamchandani JR, Nielsen TO, Van de Rijn M, et al. Sox10 and S100 in the diagnosis of soft-Tissue neoplasms. Appl Immunohistochem Mol Morphol. 2012; 20: 445-450.
14. Baranski Z, Booij TH, Cleton-Jansen AM, et al. Avenmediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. J Pathol. 2015; 236: 348-359.
15. Schaefer IM, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016; 29: 4-13.
16. Prieto-Granada CN, Wiesner T, Messina JL, et al. Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am J Surg Pathol. 2015; e-pub ahead of print
17. Subramanian S, Thayanithy V, West RB, et al. Genomewide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol. 2010; 220: 58-70.
18. Hirbe AC, Dahiya S, Miller CA, et al. Whole exome sequencing reveals the order of genetic changes during malignant transformation and metastasis in a single patient with NF1-plexiform neurofibroma. Clin Cancer Res. 2015; 21: 4201-4211.
19. Stricker TP, Henriksen KJ, Tonsgard JH, et al. Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation. Mod Pathol. 2013; 26: 930-943.
20. Garcia CB, Shaffer CM, Eid JE. Genome-wide recruitment to polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYTSSX2. BMC Genomics. 2012; 13: 189.
21. Llombart B, Monteagudo C, Sanmartin O, et al. Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors. J Am Acad Dermatol. 2011; 65: 564-575.
22. Lopez G, Bill KL, Bid HK, et al. A potential therapeutic target for the treatment of malignant peripheral nerve sheath tumors (MPNST). PLoS ONE. 2015; 10: e0133302.
23. Lopez G, Torres K, Liu J, et al. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011; 71: 185-196.